CENITRES: producción artículos publicados en revistas indexadas internacionales (desde su creación en 2023 hasta Julio 2025)
2025
#1
Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications.
Pirola CJ, Diambra L, Fernández Gianotti T, Castaño GO, San Martino J, Garaycoechea M, Sookoian S. Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001346. Online ahead of print. PMID: 40310655
#2
Valproate decreases transgenerationally blood pressure by affecting thyrotropin-releasing hormone promoter DNA methylation and gene expression in spontaneously hypertensive rat.
Landa MS, Schuman ML, Aisicovich M, Peres Diaz LS, Gironacci MM, García SI, Pirola CJ. Mol Cell Biochem. 2025 Feb;480(2):937-949. doi: 10.1007/s11010-024-05001-4. Epub 2024 Apr 17. PMID: 38630362
#3
MASLD as a non-communicable disease.
Sookoian S, Pirola CJ, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2025 Mar;22(3):148-149. doi: 10.1038/s41575-025-01039-x. PMID: 39905174
#4
Global Burden of Major Chronic Liver Diseases in 2021.
Feng G, Yilmaz Y, Valenti L, Seto WK, Pan CQ, Méndez-Sánchez N, Ye F, Sookoian S, Targher G, Byrne CD, Chan WK, Treeprasertsuk S, Yu HH, Kim SU, George J, Xu WJ, Sebastiani G, Ocama P, Ryan JD, Lupșor-Platon M, Ghazinyan H, Hamid S, Perera N, Alswat K, Isakov V, Pan Q, Sarin SK, Schattenberg JM, Sotoudeheian M, Wong YJ, Sharara AI, Al-Busafi SA, Opio CK, Chai J, Fouad Y, Shi Y, Al-Mahtab M, Zhang S, Pirola CJ, Wong VW, Zheng MH. Liver Int. 2025 Apr;45(4):e70058. doi: 10.1111/liv.70058. PMID: 40062742
#5
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.
Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, Adams LA, Boursier J, Papatheodoridis G, El-Kassas M, Méndez-Sánchez N, Sookoian S, Castera L, Chan WK, Ye F, Treeprasertsuk S, Cortez-Pinto H, Yu HH, Kim W, Romero-Gómez M, Nakajima A, Win KM, Kim SU, Holleboom AG, Sebastiani G, Ocama P, Ryan JD, Lupșor-Platon M, Ghazinyan H, Al-Mahtab M, Hamid S, Perera N, Alswat KA, Pan Q, Long MT, Isakov V, Mi M, Arrese M, Sanyal AJ, Sarin SK, Leite NC, Valenti L, Newsome PN, Hagström H, Petta S, Yki-Järvinen H, Schattenberg JM, Castellanos Fernández MI, Leclercq IA, Aghayeva G, Elzouki AN, Tumi A, Sharara AI, Labidi A, Sanai FM, Matar K, Al-Mattooq M, Akroush MW, Benazzouz M, Debzi N, Alkhatry M, Barakat S, Al-Busafi SA, Rwegasha J, Yang W, Adwoa A, Opio CK, Sotoudeheian M, Wong YJ, George J, Zheng MH. JHEP Rep. 2024 Nov 14;7(3):101271. doi: 10.1016/j.jhepr.2024.101271. eCollection 2025 Mar. PMID: 39980749 Free PMC article.
#6
Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021.
Wu C, Targher G, Byrne CD, Mao Y, Cheung TT, Yilmaz Y, Valenti L, Méndez-Sánchez N, Sookoian S, Chan WK, Treeprasertsuk S, Yu HH, Kim SU, George J, Hu D, Sebastiani G, Ryan JD, Oviedo RJ, Zhong JH, Schattenberg JM, Lonardo A, Ruiz-Úcar E, Seto WK, Sotoudeheian M, Ocama P, Lupşor-Platon M, Yang T, Ghazinyan H, Pan Q, Hamid S, Adams L, Chai J, Prasad A, Perera N, Alswat K, Isakov V, Sarin SK, Sharara AI, Sanai FM, Al-Busafi SA, Opio CK, Toro-Huamanchumo CJ, Yang W, Wong YJ, Torzilli G, Fouad Y, Zheng MH. Am J Gastroenterol. 2025 Jan 3. doi: 10.14309/ajg.0000000000003288. Online ahead of print. PMID: 39749919
#7
The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions.
Pirola CJ, Fernández Gianotti T, Sookoian S. Aliment Pharmacol Ther. 2025 Feb;61(4):614-627. doi: 10.1111/apt.18468. Epub 2025 Jan 2. PMID: 39744897 Review.
#8
Identifying molecular pathways of olfactory dysfunction in Parkinson's disease through a systems biology framework.
Glasbauer ND, Sookoian S, Pirola CJ. Neuroscience. 2025 Jun 21;577:264-271. doi: 10.1016/j.neuroscience.2025.05.031. Epub 2025 May 20. PMID: 40398724
#9
Repurposing Daclatasvir for MASLD Therapy - A Promising Step Forward with Challenges Ahead.
Pirola CJ. J Lipid Res. 2025 Jul 3:100857. doi: 10.1016/j.jlr.2025.100857. Online ahead of print. PMID: 40617356
2024
#1
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15-39, 1990-2021.
Zhou XD, Chen QF, Targher G, Byrne CD, Mantzoros CS, Zhang H, Lonardo A, Lip GYH, Porta G, Misra A, Robertson AG, Luo F, Alisi A, Yang W, El-Shabrawi M, Al Momani H, Somers VK, Katsouras CS, Méndez-Sánchez N, Lefere S, Szepietowski O, Sung KC, Hui Ng NB, Valenti L, Lee WS, Pik-Shan Kong A, Kızılkaya MC, Ocama P, Ali A, Viveiros O, Ryan JD, Toro-Huamanchumo CJ, Perera N, Ataya K, Yen Kok KY, Gracia-Sancho J, Sharara AI, Prasad A, Oviedo RJ, Ospanov O, Ruiz-Úcar E, Alswat K, Abbas SI, Abdelbaki TN, Wong YJ, Fouad Y, Shapiro MD, Bacopoulou F, Sookoian S, Kehar M, Chan WK, Treeprasertsuk S, Adams L, Turan S, Zuluaga M, Pirola CJ, Thaher O, Molina GA, Jumaev NA, Al-Busafi SA, Opio CK, Lim-Loo MC, Adithya Lesmana CR, Kamani L, Zheng MH. Clin Nutr. 2024 Dec;43(12):391-404. doi: 10.1016/j.clnu.2024.11.016. Epub 2024 Nov 14. PMID: 39579593
#2
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments.
Pirola CJ, Landa MS, Schuman M, García SI, Salatino A, Sookoian S. Clin Mol Hepatol. 2025 Jan;31(1):179-195. doi: 10.3350/cmh.2024.0359. Epub 2024 Oct 11. PMID: 39391907
#3
Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021.
Zhou XD, Chen QF, Yang W, Zuluaga M, Targher G, Byrne CD, Valenti L, Luo F, Katsouras CS, Thaher O, Misra A, Ataya K, Oviedo RJ, Pik-Shan Kong A, Alswat K, Lonardo A, Wong YJ, Abu-Abeid A, Al Momani H, Ali A, Molina GA, Szepietowski O, Jumaev NA, Kızılkaya MC, Viveiros O, Toro-Huamanchumo CJ, Yen Kok KY, Ospanov O, Abbas SI, Robertson AG, Fouad Y, Mantzoros CS, Zhang H, Méndez-Sánchez N, Sookoian S, Chan WK, Treeprasertsuk S, Adams L, Ocama P, Ryan JD, Perera N, Sharara AI, Al-Busafi SA, Opio CK, Garcia M, Lim-Loo MC, Ruiz-Úcar E, Prasad A, Casajoana A, Abdelbaki TN, Zheng MH. EClinicalMedicine. 2024 Sep 24;76:102848. doi: 10.1016/j.eclinm.2024.102848. eCollection 2024 Oct. PMID: 39386160
#4
Global Epidemiological Impact of PNPLA3 I148M on Liver Disease.
Kozlitina J, Sookoian S. Liver Int. 2025 Mar;45(3):e16123. doi: 10.1111/liv.16123. Epub 2024 Oct 7. PMID: 39373119 Free PMC article. Review.
#5
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus.
Zeng XF, Varady KA, Wang XD, Targher G, Byrne CD, Tayyem R, Latella G, Bergheim I, Valenzuela R, George J, Newberry C, Zheng JS, George ES, Spearman CW, Kontogianni MD, Ristic-Medic D, Peres WAF, Depboylu GY, Yang W, Chen X, Rosqvist F, Mantzoros CS, Valenti L, Yki-Järvinen H, Mosca A, Sookoian S, Misra A, Yilmaz Y, Kim W, Fouad Y, Sebastiani G, Wong VW, Åberg F, Wong YJ, Zhang P, Bermúdez-Silva FJ, Ni Y, Lupsor-Platon M, Chan WK, Méndez-Sánchez N, de Knegt RJ, Alam S, Treeprasertsuk S, Wang L, Du M, Zhang T, Yu ML, Zhang H, Qi X, Liu X, Pinyopornpanish K, Fan YC, Niu K, Jimenez-Chillaron JC, Zheng MH. Metabolism. 2024 Dec;161:156028. doi: 10.1016/j.metabol.2024.156028. Epub 2024 Sep 11. PMID: 39270816
#6
Global burden of metabolic diseases, 1990-2021.
Zhang H, Zhou XD, Shapiro MD, Lip GYH, Tilg H, Valenti L, Somers VK, Byrne CD, Targher G, Yang W, Viveiros O, Opio CK, Mantzoros CS, Ryan JD, Kok KYY, Jumaev NA, Perera N, Robertson AG, Abu-Abeid A, Misra A, Wong YJ, Ruiz-Úcar E, Ospanov O, Kızılkaya MC, Luo F, Méndez-Sánchez N, Zuluaga M, Lonardo A, Al Momani H, Toro-Huamanchumo CJ, Adams L, Al-Busafi SA, Sharara AI, Chan WK, Abbas SI, Sookoian S, Treeprasertsuk S, Ocama P, Alswat K, Kong AP, Ataya K, Lim-Loo MC, Oviedo RJ, Szepietowski O, Fouad Y, Zhang H, Abdelbaki TN, Katsouras CS, Prasad A, Thaher O, Ali A, Molina GA, Sung KC, Chen QF, Lesmana CRA, Zheng MH. Metabolism. 2024 Nov;160:155999. doi: 10.1016/j.metabol.2024.155999. Epub 2024 Aug 14. PMID: 39151887
#7
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.
Sookoian S, Rotman Y, Valenti L. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2177-2187.e3. doi: 10.1016/j.cgh.2024.05.052. Epub 2024 Jul 31. PMID: 39094912 Review.
#8
Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis.
Pirola CJ, Sookoian S. Prog Mol Biol Transl Sci. 2024;207:193-206. doi: 10.1016/bs.pmbts.2024.01.006. Epub 2024 May 11. PMID: 38942537
#9
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.
Zhang H, Targher G, Byrne CD, Kim SU, Wong VW, Valenti L, Glickman M, Ponce J, Mantzoros CS, Crespo J, Gronbaek H, Yang W, Eslam M, Wong RJ, Machado MV, Yu ML, Ghanem OM, Okanoue T, Liu JF, Lee YH, Xu XY, Pan Q, Sui M, Lonardo A, Yilmaz Y, Zhu LY, Moreno C, Miele L, Lupsor-Platon M, Zhao L, LaMasters TL, Gish RG, Zhang H, Nedelcu M, Chan WK, Xia MF, Bril F, Shi JP, Datz C, Romeo S, Sun J, Liu D, Sookoian S, Mao YM, Méndez-Sánchez N, Wang XY, Pyrsopoulos NT, Fan JG, Fouad Y, Sun DQ, Giannini C, Chai J, Xia ZF, Jun DW, Li GJ, Treeprasertsuk S, Li YX, Cheung TT, Zhang F, Goh GB, Furuhashi M, Seto WK, Huang H, Di Sessa A, Li QH, Cholongitas E, Zhang L, Silveira TR, Sebastiani G, Adams LA, Chen W, Qi X, Rankovic I, De Ledinghen V, Lv WJ, Hamaguchi M, Kassir R, Müller-Wieland D, Romero-Gomez M, Xu Y, Xu YC, Chen SY, Kermansaravi M, Kuchay MS, Lefere S, Parmar C, Lip GYH, Liu CJ, Åberg F, Lau G, George J, Sarin SK, Zhou JY, Zheng MH; MAFLD ICD-11 coding collaborators. Hepatol Int. 2024 Aug;18(4):1178-1201. doi: 10.1007/s12072-024-10702-5. Epub 2024 Jun 15. PMID: 38878111
#10
Resmetirom for treatment of MASH.
Sookoian S, Pirola CJ. Cell. 2024 Jun 6;187(12):2897-2897.e1. doi: 10.1016/j.cell.2024.05.009. PMID: 38848671
#11
Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease.
Pirola CJ, Salatino A, Fernández Gianotti T, Castaño GO, Garaycoechea M, Sookoian S. EBioMedicine. 2024 Mar;101:104996. doi: 10.1016/j.ebiom.2024.104996. Epub 2024 Feb 5. PMID: 38320344 Free PMC article.
#12
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective.
Pirola CJ, Sookoian S. Clin Mol Hepatol. 2024 Apr;30(2):174-176. doi: 10.3350/cmh.2024.0082. Epub 2024 Feb 5. PMID: 38311818 Free PMC article. No abstract available.
#13
From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.
Rinella ME, Sookoian S. J Lipid Res. 2024 Jan;65(1):100485. doi: 10.1016/j.jlr.2023.100485. Epub 2023 Dec 14. PMID: 38103785 Free PMC article. No abstract available.
#14
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
2023
#1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24. PMID: 37364790 Free article. Review.
#2
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. PMID: 37363821 Free PMC article.
#3
A global research priority agenda to advance public health responses to fatty liver disease.
Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM; Healthy Livers, Healthy Lives Collaborators. J Hepatol. 2023 Sep;79(3):618-634. doi: 10.1016/j.jhep.2023.04.035. Epub 2023 Jun 20. PMID: 37353401 Free article.
#4
SARS-CoV-2 targets the liver and manipulates glucose metabolism.
Pirola CJ, Sookoian S. Trends Mol Med. 2023 Sep;29(9):681-683. doi: 10.1016/j.molmed.2023.06.001. Epub 2023 Jun 7. PMID: 37330366 Free PMC article.